Literature DB >> 26679865

Discordant bone marrow involvement in non-Hodgkin lymphoma.

Jennifer Brudno1, Tamar Tadmor2, Stefania Pittaluga3, Alina Nicolae3, Aaron Polliack4, Kieron Dunleavy1.   

Abstract

A discordant lymphoma occurs where 2 distinct histologic subtypes coexist in at least 2 separate anatomic sites. Histologic discordance is most commonly observed between the bone marrow (BM) and lymph nodes (LNs), where typically aggressive lymphoma is found in a LN biopsy with indolent lymphoma in a BM biopsy. Although the diagnosis of discordance relied heavily on histopathology alone in the past, the availability of flow cytometry and molecular studies have aided the identification of this entity. The true prevalence and clinical ramifications of discordance remain controversial as available data are principally retrospective, and there is therefore little consensus to guide optimal management strategies. In this review, we examine the available literature on discordant lymphoma and its outcome, and discuss current therapeutic approaches. Future studies in discordant lymphoma should ideally focus on a large series of patients with adequate tissue samples and incorporate molecular analyses.

Entities:  

Mesh:

Year:  2015        PMID: 26679865      PMCID: PMC4768431          DOI: 10.1182/blood-2015-06-651968

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Concordant and discordant bone marrow involvement in diffuse large B-cell lymphoma: are they understudied phenomena?

Authors:  Luciano Wannesson; Ekaterina Chigrinova
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.

Authors:  N Keldsen; W Michalski; S M Bentzen; K B Hansen; K Thorling
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

3.  The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma.

Authors:  Inas El-Najjar; Silvia Montoto; Amy McDowell; Janet Matthews; John Gribben; Teresa A Szyszko
Journal:  Nucl Med Commun       Date:  2014-03       Impact factor: 1.690

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  [Two cases of discordant lymphomas consisting of MALT lymphoma and follicular lymphoma].

Authors:  Masaaki Noda; Natsuki Miyoshi; Shinichi Takada; Miho Tarutani; Akira Sakai
Journal:  Rinsho Ketsueki       Date:  2011-07

6.  Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.

Authors:  M G Conlan; M Bast; J O Armitage; D D Weisenburger
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

7.  Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Laurie H Sehn; David W Scott; Mukesh Chhanabhai; Brian Berry; Anna Ruskova; Leanne Berkahn; Joseph M Connors; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

8.  Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Authors:  E Pelosi; P Pregno; D Penna; D Deandreis; A Chiappella; G Limerutti; U Vitolo; M Mancini; G Bisi; E Gallo
Journal:  Radiol Med       Date:  2008-04-14       Impact factor: 3.469

9.  Discordant malignant lymphoma synchronous or successive high-grade B lymphoma associated with Hodgkin's disease. A clinico pathologic and immunophenotypic study of 4 cases.

Authors:  D Damotte; A Le Tourneau; J Audouin; C Duval; F Martin-Bastenaire; O Villain; A Delobelle-Deroide; J Diebold
Journal:  Pathol Res Pract       Date:  1995-02       Impact factor: 3.250

10.  Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications.

Authors:  D E Fisher; J O Jacobson; K A Ault; N L Harris
Journal:  Cancer       Date:  1989-11-01       Impact factor: 6.860

View more
  5 in total

1.  Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma.

Authors:  Atsujiro Nishioka; Hiroshi Ureshino; Toshihiko Ando; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Hidekazu Itamura; Yasushi Kubota; Kensuke Kojima; Koichi Ohshima; Shinya Kimura
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

2.  Diffuse large B-cell lymphoma: morphologic and immunohistochemical analysis of bone marrow for staging, with emphasis on lymphoid aggregates.

Authors:  Vinicius C Nóbrega; Maria A C Domingues; Lígia Niero-Melo; Cristiano C Oliveira
Journal:  Int J Clin Exp Pathol       Date:  2022-09-15

3.  Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.

Authors:  Seok Jin Kim; Jun Sik Hong; Myung Hee Chang; Jeong-A Kim; Jae-Yong Kwak; Jin Seok Kim; Dok Hyun Yoon; Won Sik Lee; Young Rok Do; Hye Jin Kang; Hyeon-Seok Eom; Yong Park; Jong-Ho Won; Yeung-Chul Mun; Hyo Jung Kim; Jung Hye Kwon; Jee Hyun Kong; Sung Yong Oh; Sunah Lee; Sung Hwa Bae; Deok-Hwan Yang; Hyun Jung Jun; Yang Soo Kim; Hwan Jung Yun; Soon Il Lee; Min Kyoung Kim; Eun Kyung Park; Won Seog Kim; Cheolwon Suh
Journal:  Oncotarget       Date:  2016-11-01

Review 4.  How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Authors:  Christian Gisselbrecht; Eric Van Den Neste
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

5.  Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Authors:  Mihai Merzianu; Adrienne Groman; Alan Hutson; Claudiu Cotta; Russell K Brynes; Attilio Orazi; Vishnu Reddy; Julie Teruya-Feldstein; Ramila Amre; Manjula Balasubramanian; Guilherme Brandao; Sindhu Cherian; Elizabeth Courville; David Czuchlewski; Guang Fan; David Grier; Daniela Hoehn; Kedar V Inamdar; Ridas Juskevicius; Prabhjot Kaur; John Lazarchick; Michael R Lewis; Rodney R Miles; Jerome B Myers; Michel R Nasr; Hina N Qureishi; Horatiu Olteanu; Valentin G Robu; Gratian Salaru; Neerja Vajpayee; Jeffrey Vos; Ling Zhang; Shanxiang Zhang; Le Aye; Elisa Brega; James E Coad; John Grantham; Sinisa Ivelja; Robert McKenna; Kieran Sultan; Gregory Wilding; Robert Hutchison; LoAnn Peterson; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2018-10-01       Impact factor: 2.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.